Vivo Capital

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.

Arrowhead and Vivo formed Visirna Therapeutics as a joint venture to bring four of the biotech's RNAi therapies to China. Through a licensing agreement, the company will focus on four of Arrowhead's therapies for cardiometabolic diseases.

Ocelot Bio brings new treatment options to patients with severe liver disease. The company was founded in 2020 and is headquartered in San Diego, California.

Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

HistoWiz, Inc. is a histology service company based in Brooklyn, New York, that specializes in automating the processing and digitization of tissue samples for cancer research in both academia and the pharmaceutical industry. Established in 2012, HistoWiz operates a fully automated histology lab and features an innovative online pathologist network. The company processes, embeds, cuts, and stains mouse tissue specimens, which are then stored in PathologyMap, a cloud-based database. This platform serves as a valuable resource for cancer researchers by facilitating the integration of technology and the development of artificial intelligence tools for digital pathology. By enhancing data management and enabling efficient information exchange among medical scientists and research pathologists, HistoWiz aims to accelerate pathology-based research and contribute to the search for cures.

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Aadi Bioscience, Inc. is a clinical stage biopharmaceutical company based in Pacific Palisades, California, founded by Dr. Neil Desai in 2011. The company focuses on the development of a potentially best-in-class mTOR inhibitor, specifically ABI-009, aimed at treating patients with oncology, cardiovascular, and metabolic diseases. Aadi Bioscience is dedicated to addressing unmet medical needs through its innovative therapeutic approaches in these areas.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that utilize radioisotopes, particularly focusing on alpha-emitting isotopes like Actinium-225 for the treatment of solid tumors. RayzeBio aims to improve cancer treatment outcomes by creating a robust pipeline of radiopharmaceuticals targeting validated oncology drug targets. Its portfolio includes multiple drug candidates at various stages of development, ranging from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Esco Lifesciences Group specializes in providing technology-based products and services aimed at the life sciences and healthcare sectors. The company supports various aspects of academic research, scientific discoveries, clinical practice, and biopharmaceutical research and development. Its offerings are designed to facilitate the invention, discovery, and commercialization processes in the industry, ultimately enabling customers to lead healthier and safer lives through advanced technological solutions.

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Aerobiotix is a privately held company specializing in the development and manufacture of proprietary environmental management devices for use in institutional healthcare, home health, and commercial settings.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, founded in 2008. The company specializes in developing diagnostic tests aimed at predicting a woman's individualized risk of premature birth, preeclampsia, and other pregnancy-related complications. By utilizing proprietary biomarkers, Sera Prognostics seeks to address the significant economic and healthcare challenges associated with premature births, impacting infants, families, and society at large. The company has licensed advanced serum proteomics technology and innovative peptides from Brigham Young University and the University of Utah to support its research and development efforts.

Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic therapies aimed at treating cancer. Immune-Onc Therapeutics focuses on the tumor microenvironment and immune suppressive pathways, utilizing advanced scientific insights to create novel immuno-oncology products. The company employs a targeted approach to develop first-in-class therapeutic antibodies that disarm immune suppression in tumors, thereby enhancing the immune response against cancer. Through its differentiated pipeline, Immune-Onc Therapeutics aims to provide new treatment options for cancer patients, addressing critical needs in the field of immunology and oncology.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, with a focus on developing innovative antibody-drug conjugate therapies for late-stage multiple myeloma and prostate cancer. The company was established based on technology exclusively licensed from the University of California, San Francisco, and developed in the laboratory of Dr. Bin Liu. Fortis Therapeutics aims to enhance treatment options for patients suffering from advanced adenocarcinoma and neuroendocrine cancer, leveraging its proprietary platform to create targeted therapies that improve clinical outcomes in late-stage cancer treatment.

Ossium Health, Inc. is focused on developing and manufacturing cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers several key products, including HPC, Marrow, which consists of HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, designed to enhance organ transplantation; and Chymalis, a cell therapy product utilizing mesenchymal stem cells from bone marrow to aid in the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and based in San Francisco, California, Ossium is also establishing the world's first bone marrow bank to improve treatment outcomes for blood cancers and facilitate tissue repair.

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Design Therapeutics, Inc. is a clinical-stage biotechnology company based in Solana Beach, California, focused on developing innovative therapies for degenerative disorders resulting from nucleotide repeat expansions. Founded in 2017, the company is advancing its lead program aimed at treating Friedreich's ataxia, while also exploring treatment options for other conditions such as Fragile X syndrome and myotonic dystrophy. Design Therapeutics is known for its GeneTACTM molecules, a new class of small-molecule gene-targeted therapies designed to address the underlying causes of diseases linked to inherited nucleotide repeat expansion mutations. The company's ongoing research efforts seek to develop disease-modifying treatments for serious conditions driven by these genetic factors.

IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.

Visen Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of innovative endocrine drugs. The company aims to address significant unmet medical needs for patients in Greater China, focusing specifically on endocrine treatment solutions. By leveraging its expertise in biotechnology, Visen Pharmaceuticals seeks to improve patient outcomes through the creation of effective therapies in the field of endocrinology.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.

Provivi Inc. develops biopesticides for agriculture, commercial, household, and public health pest management. It develops research quantities of carbene/nitrene transferase enzymes that activate diazo and azide compounds to generate iron-carbenoids and iron-nitrenoids through a mode of activation. The company also develops a biocatalysis and fermentation technology, which is based on biocatalysts that enable efficient synthesis of biopesticides. Its technology has applications in industries, such as pharmaceuticals, nutrition, flavors, and fragrances. The company offers its products through distributors worldwide. Provivi Inc. was incorporated in 2012 and is based in Santa Monica, California.

Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, the company focuses on developing targeted therapies that inhibit specific genetic alterations associated with cancer progression. Its lead candidate, seribantumab, is designed to address tumor growth driven by NRG1 fusions and is currently undergoing clinical evaluation in the Phase 2 CRESTONE study, which includes patients with various tumor types exhibiting this genomic alteration. Through its innovative approach, Elevation Oncology aims to enhance treatment options for individuals with solid tumors linked to specific genetic drivers.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing innovative cell therapies for cancer treatment. The company's lead product candidates include GC012F, a dual-targeted CAR-T therapy for multiple myeloma currently in Phase I trials; GC019F, which targets adult B cell acute lymphoblastic leukemia and is also in Phase I trials; and GC007F, aimed at B cell non-Hodgkin’s lymphoma, also in Phase I. Additionally, Gracell is developing GC027, a CAR-T candidate targeting adult T cell acute lymphoblastic leukemia, and GC007g, an allogeneic CAR-T therapy for relapsed or refractory B-ALL, both in Phase I trials. Beyond these, Gracell has a pipeline of earlier-stage product candidates targeting various cancers, including ovarian and breast cancer. Founded in 2017, Gracell Biotechnologies is committed to advancing cellular therapeutics to improve patient outcomes in hematological malignancies and solid tumors.

Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.

Tranquis Therapeutics, Inc., a biotechnology company, engages in developing immuno-therapeutics for neurodegenerative and aging-related diseases. Its TQS-168 is a therapeutic candidate that targets underlying myeloid immune cell dysfunction that is linked to a variety of nervous system disorders. Its solution is used to treat amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, and age-related cognitive impairment. The company was incorporated in 2016 and is based in San Mateo, California.

Bolt Biotherapeutics is a biotechnology company focused on developing innovative cancer treatments through its Boltbody platform, which centers on immune-stimulating antibody conjugates (ISAC). This platform combines tumor-targeting antibodies with potent immune stimulants, such as TLR agonists, to transform cold tumors into immunologically active ones and facilitate tumor elimination. One of the company's key developments is BDC-1001, designed as a monotherapy for patients with HER2-expressing solid tumors. Founded in 2015 and headquartered in Redwood City, California, Bolt Biotherapeutics aims to advance cancer immunotherapy and improve patient outcomes. The company was previously known as Bolt Therapeutics before rebranding in July 2015.

Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for oncology and other medical conditions. Its primary product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy aimed at treating multiple myeloma by targeting the B-cell maturation antigen. The company is actively conducting clinical trials to assess this therapy as an earlier treatment option and to compare its effectiveness against standard triplet therapy in patients resistant to Revlimid. Additionally, Legend Biotech has a diverse portfolio of earlier-stage autologous product candidates that address various cancers, including non-Hodgkin lymphoma, acute myeloid leukemia, and T cell lymphoma. The company is also developing an allogeneic CAR-T product candidate targeting CD20, currently in a Phase 1 clinical trial in China. Besides its focus on blood cancers, Legend Biotech is exploring therapies for solid tumors and infectious diseases. Founded in 2014 and based in Somerset, New Jersey, Legend Biotech operates as a subsidiary of Genscript Biotech Corporation.

RemeGen Co., Ltd. is a biopharmaceutical company based in Yantai, China, that focuses on the discovery, development, and commercialization of biologics aimed at addressing unmet medical needs in autoimmune, oncology, and ophthalmic diseases. Established in 2008, RemeGen specializes in innovative biologics, including monoclonal antibodies and antibody-drug conjugates. Its key products under development include Telitacicept, which targets autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, and Disitamab Vedotin for various cancers. The company is also advancing other candidates like RC28 and RC88 for retinal conditions, alongside several pre-clinical products aimed at treating solid tumors. RemeGen operates primarily in China but also maintains laboratories and offices in Beijing and California, emphasizing its commitment to fulfilling the medical needs of patients with life-threatening conditions.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.

Genetron Health is a world-leading expert in precision medicine.They are committed to developing health management products that cover all elements of full-cycle cancer clinical treatment (including risk assessment, early screening, molecular pathology diagnosis, medication guidance and prognosis monitoring) and effectively applying genomic data to assist medical experts and research scientists. Additionally, they provide cancer patients and high-risk and healthy individuals with reliable molecular clinical services and professional cancer genetic risk assessment.In just three years, Genetron Health has built global genomics sequencing and bioinformatics platforms, established two research and development centers in both North Carolina, U.S., and Beijing, China, and set up clinical laboratories in Beijing, Shanghai, Hangzhou and Chongqing of over 10,000 square meters.In the future, Genetron Health will spread its sales network throughout China with professional marketing, product management, medical experts and scientific research teams, and will provide service for Chinese and global cancer patients with its strong foundation in cancer genomics and efficient clinical translation.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, and we have initiated a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL) patients in 2019. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with solid and hematologic malignancies, for which we have recently initiated a Phase 1 clinical trial. Also in our product pipeline is IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing innovative therapies for patients with significant unmet medical needs. The company is advancing a diverse pipeline that includes treatments for hematological malignancies and solid tumors, as well as liver-directed gene therapies aimed at rare diseases. Poseida is known for its proprietary gene engineering platforms, including the non-viral piggyBac DNA Modification System and the Cas-CLOVER site-specific gene editing system, which facilitate the creation of next-generation cell and gene therapeutics. Additionally, the company's portfolio encompasses CAR-T therapies for cancer and gene therapies targeting rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia. Founded in 2014, Poseida Therapeutics is committed to addressing critical health challenges through its advanced therapeutic solutions.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Bolt Biotherapeutics is a biotechnology company focused on developing innovative cancer treatments through its Boltbody platform, which centers on immune-stimulating antibody conjugates (ISAC). This platform combines tumor-targeting antibodies with potent immune stimulants, such as TLR agonists, to transform cold tumors into immunologically active ones and facilitate tumor elimination. One of the company's key developments is BDC-1001, designed as a monotherapy for patients with HER2-expressing solid tumors. Founded in 2015 and headquartered in Redwood City, California, Bolt Biotherapeutics aims to advance cancer immunotherapy and improve patient outcomes. The company was previously known as Bolt Therapeutics before rebranding in July 2015.

Visen Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of innovative endocrine drugs. The company aims to address significant unmet medical needs for patients in Greater China, focusing specifically on endocrine treatment solutions. By leveraging its expertise in biotechnology, Visen Pharmaceuticals seeks to improve patient outcomes through the creation of effective therapies in the field of endocrinology.

Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic therapies aimed at treating cancer. Immune-Onc Therapeutics focuses on the tumor microenvironment and immune suppressive pathways, utilizing advanced scientific insights to create novel immuno-oncology products. The company employs a targeted approach to develop first-in-class therapeutic antibodies that disarm immune suppression in tumors, thereby enhancing the immune response against cancer. Through its differentiated pipeline, Immune-Onc Therapeutics aims to provide new treatment options for cancer patients, addressing critical needs in the field of immunology and oncology.

TOT Biopharm Company Limited is a clinical-stage biopharmaceutical firm based in Suzhou, China, focused on the development, manufacture, and marketing of innovative oncology drugs and therapies. Founded in 2010, the company specializes in therapeutic biological products, particularly anti-tumor drugs and specialty medicines. One of its notable products is S-1, an oral medication that combines tegafur, gimeracil, and oteracil potassium, designed to enhance the delivery and efficacy of 5-fluorouracil, a key chemotherapeutic agent. TOT Biopharm is committed to establishing a trusted brand in oncology treatments, with a diverse pipeline that includes monoclonal antibodies and antibody-drug conjugates aimed at improving patient outcomes in cancer care. The company's operations primarily generate revenue in Mainland China.

Sinovac Biotech Ltd. is a biopharmaceutical company based in Beijing, China, specializing in the research, development, manufacture, and commercialization of vaccines for human infectious diseases. Its product portfolio includes vaccines for hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza, mumps, and enterovirus 71, among others. Key marketed products include Healive, a hepatitis A vaccine, Bilive, a combined hepatitis A and B vaccine, and Panflu.1, which was the first H1N1 vaccine approved globally. Sinovac also plays a significant role in government stockpiling programs for vaccines in China. The company is actively developing new vaccines, including those for pneumococcal disease and rubella, with various clinical trials underway. Sinovac collaborates with notable institutions such as GlaxoSmithKline and Tianjin CanSino Biotechnology to enhance its vaccine development efforts. Established in 1999, Sinovac primarily sells its products in China while also exporting selected vaccines to countries like Mongolia, Nepal, and the Philippines.

Precision BioSciences, Inc. is a biotechnology company that specializes in genome editing, utilizing its proprietary ARCUS platform to develop therapeutic and food products. The Therapeutic segment focuses on creating allogeneic CAR T immunotherapies aimed at treating various cancers, including acute lymphoblastic leukemia and multiple myeloma, with several candidates currently in clinical trials. Notable product candidates include PBCAR0191, targeting CD19, and PBCAR269A, targeting BCMA. Additionally, the company is engaged in in vivo gene correction and has collaborations for developing treatments for chronic Hepatitis B. The Food segment aims to innovate in food and nutrition products. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences is committed to translating advanced genome editing technology into impactful medical and agricultural solutions.

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing innovative therapies for patients with significant unmet medical needs. The company is advancing a diverse pipeline that includes treatments for hematological malignancies and solid tumors, as well as liver-directed gene therapies aimed at rare diseases. Poseida is known for its proprietary gene engineering platforms, including the non-viral piggyBac DNA Modification System and the Cas-CLOVER site-specific gene editing system, which facilitate the creation of next-generation cell and gene therapeutics. Additionally, the company's portfolio encompasses CAR-T therapies for cancer and gene therapies targeting rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia. Founded in 2014, Poseida Therapeutics is committed to addressing critical health challenges through its advanced therapeutic solutions.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.

Medeor Therapeutics, Inc. specializes in the research, development, and commercialization of personalized cellular immunotherapies aimed at enhancing outcomes for organ transplant recipients. The company focuses on creating innovative cellular immunotherapy products, particularly for kidney transplant patients, under the MDR-10X brand. By employing advanced approaches to organ transplant immune tolerance and immuno-oncology, Medeor Therapeutics seeks to improve kidney function and reduce the risk of graft rejection more effectively than traditional immunosuppressive medications. Founded in 2012, the company is headquartered in San Mateo, California.

Amyris, Inc. is a biotechnology company based in Emeryville, California, founded in 2003. The company specializes in developing technology that creates microbial strains for the production of various high-value ingredients derived from renewable plant-sourced sugars. Its innovative platform enables the engineering of microbes to convert these sugars into products for the clean health and beauty, flavor and fragrance, and industrial markets, including cosmetics, solvents, lubricants, and fuels. Amyris operates under several brands, such as Biossance and Purecane, and is involved in biopharmaceutical drug discovery and production. Additionally, the company collaborates with the Infectious Disease Research Institute to advance vaccine development, including efforts related to COVID-19. Revenue is generated through the sale of renewable products, licensing of intellectual property, and collaborative research and development services.

Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Platelet BioGenesis is a biotechnology company focused on producing donor-independent human platelets from pluripotent stem cells for clinical use. Founded in 2014 and based in Cambridge, Massachusetts, the company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. Platelet BioGenesis distributes these bioreactor-produced platelets to hospitals and blood banks, aiming to provide a reliable source of platelets for patients worldwide. By specializing in the fields of platelets and drug discovery, the company is addressing critical needs in the medical community related to blood supply and treatment options.

Aadi Bioscience, Inc. is a clinical stage biopharmaceutical company based in Pacific Palisades, California, founded by Dr. Neil Desai in 2011. The company focuses on the development of a potentially best-in-class mTOR inhibitor, specifically ABI-009, aimed at treating patients with oncology, cardiovascular, and metabolic diseases. Aadi Bioscience is dedicated to addressing unmet medical needs through its innovative therapeutic approaches in these areas.

Angiotech is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.

Bristol-Myers Squibb is a global biopharmaceutical company that focuses on the discovery, development, manufacturing, and marketing of innovative medicines for serious diseases. The company offers a range of products primarily in hematology, oncology, cardiovascular, and immunology therapeutic areas. Notable products include Opdivo, Eliquis, and Orencia, among others, which cater to various medical conditions such as cancer, stroke prevention, and rheumatoid arthritis. Bristol-Myers Squibb operates through collaborations with several partners, including Pfizer and AstraZeneca, enhancing its research and development capabilities. Founded in 1887 and headquartered in New York, the company has established a strong presence in the U.S. market, generating a significant portion of its revenue from American sales. Through its commitment to addressing critical health needs, Bristol-Myers Squibb continues to advance the field of biopharmaceuticals and improve patient outcomes.

Angiotech is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.

Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

ReadCoor, Inc. develops and commercializes a panomic spatial sequencing platform for researchers, clinicians, pharmaceutical and diagnostics companies, and patients worldwide. It offers FISSEQ, a platform that enables integration of high throughput sequencing, morphometric analysis, cellular location, and three-dimensional spatial imaging. The company’s platform also enables researchers to perform RNA-Seq while preserving sample morphology and simultaneously providing cellular location and spatial image data. ReadCoor, Inc. was incorporated in 2016 and is based in Cambridge, Massachusetts. As of October 13, 2020, ReadCoor, Inc. operates as a subsidiary of 10x Genomics, Inc.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, with a focus on developing innovative antibody-drug conjugate therapies for late-stage multiple myeloma and prostate cancer. The company was established based on technology exclusively licensed from the University of California, San Francisco, and developed in the laboratory of Dr. Bin Liu. Fortis Therapeutics aims to enhance treatment options for patients suffering from advanced adenocarcinoma and neuroendocrine cancer, leveraging its proprietary platform to create targeted therapies that improve clinical outcomes in late-stage cancer treatment.

Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in La Jolla, California.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

REGENXBIO Inc. is a clinical-stage biotechnology company focused on developing gene therapy product candidates that utilize its proprietary NAV Technology Platform, which is based on adeno-associated virus (AAV) gene delivery. This platform aims to address genetic defects and enable cells to produce therapeutic proteins or antibodies to combat various diseases. The company's lead candidate, RGX-314, is currently undergoing Phase I/IIa clinical trials for wet age-related macular degeneration. Other notable product candidates include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia, all in various stages of clinical trials. Additionally, REGENXBIO licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has partnered with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company based in Redwood City, California, that specializes in the development, manufacture, and marketing of biosimilar therapeutics. It primarily targets the oncology and inflammatory disease markets with its product offerings. The company's flagship product, UDENYCA, is a biosimilar to Neulasta, designed to stimulate the production of granulocytes to enhance the body’s infection-fighting capabilities. Coherus is also advancing several other biosimilar candidates, including those for Humira and Enbrel, which have completed Phase III clinical studies. Additionally, the company is working on biosimilars for other biologics, including ranibizumab and aflibercept, as well as a small-molecule drug for metabolic conditions. Coherus BioSciences was founded in 2010 and has established various license agreements to support its product development initiatives.

Nora Therapeutics, Inc. is a biotechnology company that focuses on developing therapeutics to address unmet needs in reproductive medicine. Its product includes NT100, a biologic agent similar to a naturally occurring protein in the female reproductive tract that may reduce the risk of miscarriage by optimizing maternal-fetal immune tolerance in women who have a history of unexplained recurrent miscarriage. Nora Therapeutics, Inc. was formerly known as Nora, LLC. The company was founded in 1992 and is based in Palo Alto, California.

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.

ViOptix, Inc. specializes in tissue oximetry technology that measures local tissue oxygen saturation. The company offers the T.Ox Tissue Oximeter, a portable unit featuring a color LCD touchscreen, which can operate with one or two channels and supports up to two fiber optic sensors. Its product line also includes Wi-Fi enabled T.Ox Remote Monitoring devices for wireless data transmission, one-time use T.Ox Small Patch sensors for continuous StO2 monitoring, and T.Ox Silicone Surround sensors for monitoring new flap applications. ViOptix's technology has applications across various fields, including plastic surgery, intraoperative and postoperative monitoring, wound healing assessment, detection of peripheral vascular disease, and critical care. Founded in 1999 and headquartered in Fremont, California, the company was previously known as Photonify Technologies, Inc. before rebranding in 2003. Its first product, the ODISsey System, received FDA clearance in 2005 for measuring localized tissue oxygenation in critical care settings.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's pipeline includes several immuno-oncology candidates, such as Margetuximab, a monoclonal antibody currently in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include various monoclonal antibodies targeting immune checkpoints like PD-1 and B7-H3, as well as combination therapies that leverage multiple targets. MacroGenics employs advanced Fc engineering technology to enhance antibody functionality and is also exploring applications for autoimmune disorders and infectious diseases. The company has established strategic collaborations with several partners to advance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics to address significant medical needs.

Cotherix is a biopharmaceutical company dedicated to licensing, developing, and commercializing therapeutic products aimed at treating cardiopulmonary and other chronic diseases. The company's primary product, Ventavis, is an inhaled formulation of iloprost designed specifically for the treatment of pulmonary arterial hypertension in patients exhibiting New York Heart Association Class III or IV symptoms. Through its focus on innovative therapeutic solutions, Cotherix seeks to address critical healthcare needs within the cardiopulmonary sector.

As a leader in innovative biological and low-chemical pest management solutions, AgraQuest is at the forefront of a shift in how food is grown. AgraQuest focuses on discovering, developing, manufacturing and marketing highly effective biological and low-chemical pest, disease control and yield enhancing products for the agricultural, home & garden and food safety markets. Through its Agrochemical and BioInnovations Divisions, AgraQuest provides its customers and partners with tools to create value-enhancing solutions. AgraQuest has its own direct sales force in the NAFTA crop protection markets, and sells its products through a network of distributors and partners in other global regions as well as in several non agriculture related markets. Through its Agrochemical Division, AgraQuest is redefining the agrochemical industry with the introduction of effective, innovative and environmentally responsible pest and disease control products and services. AgraQuest is the premier supplier of proprietary, data-driven biological and low-chemical technology, and unlike many conventional pesticides which are made using petroleum-based or other synthetic chemicals, AgraQuest’s products are produced from renewable, bio-based materials. As part of the clean-tech revolution, AgraQuest’s BioInnovations Division is developing cutting edge technologies for use in seed treatment, food safety, post-harvest disease control, animal health and hygiene, human nutrition, home and garden, structural pest control, and vector control. Additional applications for AgraQuest’s technologies lie in areas as diverse as detergents, cosmetics and healthcare.

Copernicus Therapeutics, Inc. (CTI) is a clinical stage biopharmaceutical company and a leader in the emerging field of precision medicine and gene therapy. Through their proprietary, non-viral, nucleic acid nanoparticle platform, they are able to achieve robust gene transfer in several tissues without the immune response and limited treatment window of AAV.